| |
| | | Year : 2010 | Volume : 21 | Issue : 4 | Page : 745 | | | Authors's Reply | | | Ayham Haddad1, Rabe'a Abbadi2, Ann Marji3
1 Nephrology Division, King Hussein Medical Center, Amman, Jordan
2 Clinical Pharmacy Department, King Hussein Medical Center, Amman, Jordan
3 Princess Muna College of Nursing, Muta'a University, Amman, Jordan
Click here for correspondence address and email | Date of Web Publication | 26-Jun-2010 | | |      | | How to cite this article:
Haddad A, Abbadi R, Marji A. Authors's Reply. Saudi J Kidney Dis Transpl 2010;21:745 |
To the Editor,
We thank Gupta et al for their interest in our study. (1) First of all in our study of 205 patients we found 7.3% having hypersensitivity in contrast to the literature.(2) Secondly, the aim of the study was to illustrate the safety of two different IV Iron preparations and not to examine the cause of failure to respond to IV Iron and Erythropoietin. Thirdly, all our patients were treated with oral iron therapy before using iron sucrose injections. Fourthly, we agree that measurement of TSAT, red cell hemoglobin content and parathyroid hormone levels would have been done, however we as a routine protocol replace iron via parenteral route and further studying the iron stores is done if needed. Presentation of data about parathyroid hormone levels and even iron stores was not the aim of the study since we conducted the comparison for documentation of the safety of paranteral iron sucrose.
Correspondence Address:
Ayham Haddad
Nephrology Division, King Hussein Medical Center, Amman
Jordan
| |
| | | | | | | | | | | |
| Article Access Statistics | | | Viewed | 539 | | | Printed | 25 | | | Emailed | 0 | | | PDF Downloaded | 108 | | | Comments | [Add] | | | | 
|
